Investing
AbbVie trims full-year profit forecast due to higher R&D expenses
© Reuters. Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – AbbVie Inc (NYSE:) cut full-year profit forecast due to unfavorable impact from R&D and milestone expenses, the drugmaker said on Thursday.
The company now expects adjusted profit between $10.57 and $10.97 per share, compared with $10.72 to $11.12 per share it previously expected.
Read the full article here